Meet a Researcher: Dr Nikolas Pontikos
Dr Nikolas Pontikos is a Senior Research Fellow at UCL Institute of Ophthalmology, and has been working on inherited retinal conditions for several years.
Search
Search results
Meira GTx announces positive data from phase clinical trial
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Funding paves the way for achromatopsia
A research project funded by Retina UK helped pave the way to a new gene therapy that has recently produced encouraging results in two young people with achromatopsia, a condition that causes complete colour-blindness and poor overall vision from birth.
Corporate partnerships
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Johnson & Johnson gene therapy update – What happens now?
The latest research news from Retina UK.
ReNeuron trial FAQs
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Complaints Policy
We always aim to provide a high standard of service to our community. If you are unhappy with any of our services it is important that you let us know.
Podcast: Sight Loss Survey 2025
Join Lauren as she chats with Paula McGrath, Deputy CEO of Retina UK, about the 2025 Sight Loss Survey
Sight Loss Survey 2025
We want to ensure our current and future activities are relevant and that they respond to your needs. The only way we can be confident of this is to ask about your experiences, views and what matters to you.